Date of publication: December 14, 2021 Decision of the Secretary of Health: Approved (24 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : Sputnik V Gam-COVID-Vac COVID-19 Vaccine for the Prevention of COVID-19 (December Reassessment)
COVID-19 Vaccine Sinopharm for the Prevention of COVID-19
Date of publication: November 29, 2021 Decision of the Secretary of Health: Approved (03 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : COVID-19 Vaccine Sinopharm for the Prevention of COVID-19
Whole Virion, Inactivated Coronavirus [Covaxin] for the Prevention of COVID-19
Date of publication: November 29, 2021 Decision of the Secretary of Health: Approved (03 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : Whole Virion, Inactivated Coronavirus [Covaxin] for the Prevention of COVID-19
Booster and Additional Dose for the Prevention of COVID-19
Date of publication: November 03, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : Booster and Additional Dose for the Prevention of COVID-19
SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the Prevention of COVID-19 (July Updates)
Date of publication: July 30, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : SARS-CoV-2 Vaccine (Vero Cell), Inactivated [CoronaVac] for the Prevention of COVID-19 (July Updates)